Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug ...
today announced a strategic research collaboration with privately-he Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific ...
Hosted on MSN24d
TD Cowen maintains Buy on Guardant Health, target at $42Guardant Health's shares are traded on the NASDAQ under the ticker symbol (NASDAQ ... a partnership with pharmaceutical company Boehringer Ingelheim to seek regulatory approval for Guardant360 ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...
Boehringer Ingelheim's attempt to develop the first drug therapy for impaired cognitive function in schizophrenia, a core feature of the illness, has suffered what looks like a terminal setback.
Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback